In allogeneic hemopoietic stem cell transplantation, mature donor ␣␤ T cells in the allograft promote T cell reconstitution in the recipient and mediate the graft-vs-leukemia (GVL) effect. Unfortunately, donor T cells can attack nonmalignant host tissues and cause graft-vs-host disease (GVHD). It has previously been shown that effector memory T cells not primed to alloantigen do not cause GVHD yet transfer functional T cell memory and mediate GVL. Recently, central memory T cells (T CM ) have also been reported to not cause GVHD. In contrast, in this study, we demonstrate that purified CD8
is a potentially curative therapy for hematologic malignancies, including acute and chronic leukemias and lymphomas. In an alloSCT, donor T cells in the allograft are critical for reconstituting T cell immunity in the host (1) and mediate the graft-vs-leukemia (GVL) effect (2) (3) (4) (5) . Unfortunately, donor T cells also cause graft-vs-host disease (GVHD), the broad attack by donor T cells on recipient tissues, including the skin, liver, and gastrointestinal tract. All clinical transplant protocols incorporate some type of GVHD prophylaxis, either via depletion of T cells from the allograft or through pharmacologic agents that impair T cell function. This GVHD prophylaxis impairs both GVL and immune reconstitution, and even with pharmacologic immunosuppression, GVHD remains a major source of morbidity and mortality. Preserving the positive effects of donor T cells-GVL and immune reconstitution-without GVHD remains the central challenge in the alloSCT field.
Peripheral T cells can broadly be divided into those that have never been activated by Ag (naive T cells (T N )) and Ag-experienced T cells, which include effector and memory T cells (6 -9) . Memory T cells are themselves heterogeneous and can be subdivided into effector memory (T EM ) and central memory (T CM ) fractions by surface phenotype and by function (10) . T EM (CD62L low /CCR7 Ϫ CD44 ϩ ) quickly express effector functions upon restimulation, preferentially migrate to inflamed tissues and the spleen, and are relatively excluded from peripheral lymph nodes (LN). T CM (CD62L ϩ CCR7 ϩ CD44 ϩ ) have hybrid properties of both T N and T EM . Like T N , their expression of CD62L and CCR7 promotes efficient homing to peripheral LN (8, 10 -16) . However, although their effector functions are more vigorous than T N , they are slower to mount these responses than are T EM . Nonetheless, when rechallenged with Ag, T CM have a greater proliferative capacity than do T EM , and such a property could be advantageous in both antipathogen and antitumor responses (11, (17) (18) (19) (20) (21) .
We and others (22) (23) (24) (25) (26) have previously reported that CD4 ϩ and CD8 ϩ T EM have a reduced capacity to induce GVHD. CD4 ϩ T EM are nonetheless functional and can transfer immunity to a model Ag and retain some GVL activity (22, 26) . However, much less is known about the GVHD-and GVL-inducing potential of CD8 ϩ T CM . Chen et al. (27) reported that sorted CD45RB ϩ CD62L ϩ CD44 ϩ T CM (a mix of CD4 ϩ and CD8 ϩ cells) do not cause GVHD in the B6 (H-2 b )3 BALB/c (H-2 d ) fully MHC-mismatched allogeneic bone marrow transplant (alloBMT) model. In contrast, in the present work, we demonstrate that highly purified CD8 ϩ
CD62L
ϩ CD44 ϩ T CM clearly induce GVHD, albeit less severe than that induced by T N . We did so in the same MHC-mismatched model used by Chen et al. (27) and in an MHC-matched, multiple minor histocompatibility Ag (miHA)-mismatched strain pairing. CD8
ϩ T CM were also potent mediators of GVL.
Materials and Methods

Mice
AlloBMT recipients and mice used to generate mouse model of chronicphase chronic myelogenous leukemia (mCP-CML) were 7-10 wk of age. T cell and BM donors were between 8 and 16 wk of age. C57BL/6 (B6) and BALB/c mice were obtained from the National Cancer Institute. C3H.SW mice were obtained from The Jackson Laboratory or bred at Yale from breeding pairs purchased from The Jackson Laboratory.
Cell purifications
For GVHD experiments, CD8 ϩ T cells were enriched from total spleen cells using negative selection with BioMag magnetic beads (Qiagen). Cells were incubated for 30 min on ice with the following Ab supernatants (all lab-grown): anti-CD4 (GK1.5), anti-B220 (RA3-6B2), anti-CD11b (M1/ 70), and anti-FcR (24G.2). Cells were then washed in MACS buffer (PBS, 2 mM EDTA, 0.5% BSA) and incubated with BioMag goat anti-rat magnetic beads for 30 min on ice in a T75 or T125 flask, which was then placed next to a strong magnet. Cells not bound to magnetic particles were collected and were 60 -70% CD8
ϩ . For further separations of T N and T CM , enriched CD8
ϩ cells were incubated with anti-CD8-PE (53-7.6; BD Pharmingen), anti-CD62L-Alexa488 (Mel-14, lab-prepared), and anti-CD44-allophycocyanin (Pgp-1; BD Pharmingen) for 20 min on ice, washed and resuspended in PBS with 0.5% FBS. Cells were sorted into CD8 ϩ
CD62L
ϩ CD44 Ϫ T N and CD8 ϩ CD62L ϩ CD44 ϩ T CM using a FACSAria (BD Biosciences). BM was depleted of T cells as described previously (28) . For experiments wherein intracellular cytokine expression and the in vivo CTL assay were performed, CD8
ϩ T cells were positively selected from splenocytes using anti-CD8␣ beads (Miltenyi Biotec) and the AutoMACs, stained with Abs against CD8, CD62L, and CD44, and sorted on the FACSAria as described above. For analysis of cytokine production from freshly isolated T CM and T N , splenocytes were sorted using anti-CD8-Pacific Blue (clone TIB105; lab-prepared), anti-CD44-allophycocyanin, and anti-CD62L-PE (BD Biosciences). B6 and BALB/c B cells were purified by depleting T cells from LN cells using anti-Thy1.2-biotin and streptavidin microbeads (Miltenyi Biotec) and the AutoMACs.
GVHD transplant protocol
All transplants were performed according to protocols approved by the Yale University Institutional Animal Care and Use Committee. On day 0, B6 or BALB/c mice were irradiated (1000 or 800 cGy, respectively) and reconstituted with 7 ϫ 10 6 T cell-depleted (TCD) C3H.SW or B6 BM, with no T cells, CD8 ϩ T N , or CD8 ϩ T CM (all cells given i.v.). Mice were weighed approximately every 3 days. GVHD in the B63 BALB/c model was nonlethal. On the basis of a large experience in the C3H.SW3 B6 strain pairing (28 -30) , deaths before day 13 (which occurred equally in recipients of BM alone, T N and T CM ) were attributed to the acute toxicity of transplant and not to GVHD, and these events were censured in the survival analyses.
Histological analysis
Tissues were fixed in 10% phosphate-buffered formalin, paraffin-embedded, sectioned, and stained with H&E. Slides were read by pathologists expert in skin (J.M.), liver and gastrointestinal disease (D.J.) without knowledge as to experimental group. Scoring was as described previously (28) . Images of bowel and liver were obtained with an Olympus BX40 microscope (Olympus America) using a ϫ10 eyepiece and an ϫ20 objective, with a QImaging QColor5 camera (Olympus) and QCapture software (Olympus). Images were processed with Adobe Photoshop 7.0 software (Adobe). Images of skin were obtained with an Olympus BX61 microscope (Olympus) using a ϫ10 eyepiece, ϫ20 objective, a SPOT RT Slider camera (Diagnostic Instruments), SPOT software version 4.09 (Diagnostics Instruments), followed by processing with Adobe Photoshop 8.0.
Immunofluorescent staining
Tissues were fixed in 0.7% formaldehyde overnight, followed by dehydration in 30% sucrose and freezing in Tissue-TeK OCT compound (Sakura Finetek). Sections (7 m) were incubated overnight at 4°C with 4Ј,6-diamidino-2-phenylindole and Abs against CD8 (Alexa647; clone TIB105; lab-prepared). Sections were imaged with an Olympus BX40 microscope using a ϫ10 eyepiece, a ϫ40 objective, and a Scanalytics SPOT RT Slider camera (model 2.3.1; Diagnostic Instruments) using SPOT software version 4.06 (Diagnostics Instruments). Pictures were reconstituted with Adobe Photoshop 8. To quantitate infiltration by CD8 cells, we counted CD8 cells in four ϫ40 fields, each from two mice that received only BM, three or four fields from two mice that received T N , and three or four fields from two mice that received T CM . We treated the number of CD8 cells in a field as an independent observation and compared numbers of cells using Mann-Whitney U test (GraphPad Prism).
Intracellular cytokine staining
Intracellular cytokine staining was performed as we have described previously (26) . Briefly, splenocytes and LN cells (interscapular, axillary, cervical, mesenteric, and inguinal) were harvested and cultured with phorbol myristic acid (PMA) and ionomycin for 5 h; monensin was added for the final 2 h. Before permeabilization, cells were incubated with ethidium monoazide to allow exclusion of dead cells. Cells were stained with Abs against CD45.1 (PE; BD Biosciences) and CD8 (Pacific Blue, clone TIB105, lab-prepared), permeabilized and then stained with Abs against IFN-␥ (allophycocyanin, clone XMG1.2; BD Biosciences) and TNF-␣ (FITC, clone MP6-XT22; BD Biosciences) or isotype controls (for the anti-cytokine Abs). Analysis was performed on an LSRII (BD Biosciences).
In vivo CTL assay
Equal numbers of LN-derived B cells from B6 and BALB/c mice were pooled and stained with CFSE (Invitrogen). On day 7 post BMT, 10 7 B cells were injected into BALB/c recipients of TCD donor B6 BM, with no B6 T cells, or 10 6 sort-purified B6 T CM or T N .
Cytokine measurements
Serum cytokines were measured using the Bioplex mouse Th1/Th2 panel (Bio-Rad) and a BioPlex system.
Retrovirus production and progenitor infections
MSCV2.2 expressing the human bcr-abl p210 cDNA and a non-signaling truncated form of the human low-affinity nerve growth factor receptor (NGFR) driven by an internal ribosome entry site (Mp210/NGFR) was a gift from W. Pear (University of Pennsylvania School of Medicine, Philadelphia, PA). Retroviral supernatants were generated by transfection of the Plat-E retrovirus packing cell line as described previously (28, 29, 31, 32) . p210-infected bone marrow progenitors were generated as described previously (28, 29, 32) . Briefly, B6 mice were injected on day Ϫ6 with 5 mg of 5-fluorouracil (Pharmacia & Upjohn). On day Ϫ2, BM cells were harvested and cultured in prestimulation medium (DMEM, 15% FBS, IL-3 (6 ng/ml), IL-6 (10 ng/ml), and SCF (10 ng/ml); all cytokines from PeproTech. On days Ϫ1 and 0, cells underwent "spin infection" with Mp210/ NGFR retrovirus.
GVL transplant protocol
On day 0, host mice received 900 cGy (450 cGy ϫ 2) and were reconstituted with 5 ϫ 10 6 TCD C3H.SW BM with 7 ϫ 10 5 B6 BM cells that underwent spin infection with retroviral supernatant, with or without donor CD8 ϩ T N or T CM . Cause of death was attributed to mCP-CML if mice had a high NGFR ϩ blood count on a recent analysis of peripheral blood (PB) and by spleen weight at necropsy.
Flow cytometry analysis in GVL experiments
Whole blood was stained with Abs against Gr-1 (FITC, clone RB6-8C5; BD Pharmingen), TER-119 (PE, clone TER-119; BD Pharmingen Biosciences), and NGFR (Alexa647; clone 20.4; lab-prepared), followed by RBC lysis with ACK (Cambrex BioScience). Propidium iodide was added to exclude dead cells. BM and splenocytes were stained following ACK lysis. Cells were analyzed on a FACSCalibur (BD Immunocytometry Systems), and results were analyzed with FlowJo (Tree Star).
Statistical methods
Significance for differences in weight loss was calculated by an unpaired t test evaluating measurements from all mice in a given group against all mice in a second group as we have described previously (22, 26, 28, 30) . Values of p for survival curve were calculated by log-rank test. Values of p for comparisons of histology scores and numbers of NGFR ϩ cells in blood were calculated by Mann-Whitney U test. Values of p comparing numbers of T N -or T CM -derived cells and serum cytokine measurements were calculated using an unpaired t test (GraphPad Prism).
Results
CD8 ϩ T CM induce GVHD in MHC-mismatched and MHC-matched alloBMT models
We first studied CD8
Lethally irradiated BALB/c mice were reconstituted with TCD B6 BM with no T cells or with 1 ϫ (Fig. 1A) . Beginning early post-BMT, CD8 ϩ T N recipients lost weight relative to recipients of only TCD BM (Fig. 1B) , and this weight difference persisted until the experiment was concluded. CD8
ϩ T CM recipients also lost weight relative to recipients of only TCD BM. However, at most time points past day 7, they had less weight loss than did recipients of CD8 ϩ T N , and by the conclusion of the experiment, weight change was indistinguishable from recipients of only TCD BM. Thus, as measured by weight change, CD8
ϩ T CM induced GVHD but less than did CD8 ϩ T N . Two of 14 T N recipients died before day 8, and no deaths occurred in T CM recipients. Mice were sacrificed at approximately day ϩ40 posttransplant to harvest skin, small intestine, colon, and liver for histological GVHD. In both T N and T CM recipients, GVHD was only present in the liver, manifest by periportal inflammatory infiltrates and bile duct damage ( Fig. 1C; representative pathology, Supplemental Fig. 1 ) 4 with a trend toward lower scores in T CM recipients ( p ϭ 0.086; two-tailed).
Sorted CD8 ϩ T CM had between 1 and 2% contaminating CD8 ϩ T N . Therefore, in the second of the two experiments from which data were combined in Fig. 1 , B and C, we included a group that received 2 ϫ 10 4 CD8 ϩ T N (T N control ), the number of T N in the sorted CD8 ϩ T CM . A total of 1 ϫ 10 6 CD8 ϩ T CM and CD8 ϩ T N induced both weight loss and hepatic GVHD, whereas 2 ϫ 10 4 CD8 ϩ T N induced neither ( Fig. 1, D and E). Thus, the GVHD induced by CD8 ϩ T CM was not due to contaminating CD8 ϩ T N . Next, we determined whether sorted CD8
ϩ T CM mediate GVHD in the C3H.SW(H-2 b )3 B6 (H-2 b ) MHC-matched, multiple miHA-mismatched strain pairing. Lethally irradiated B6 mice were reconstituted with C3H.SW TCD BM with no T cells or with 1.5 ϫ 10 6 CD8 ϩ T N or T CM . Recipients of only TCD C3H.SW BM did not develop GVHD, whereas most CD8 ϩ T N recipients developed clinical GVHD manifest by death ( Fig. 2A ; 40% by day 43; p ϭ 0.0029 comparing BM and T N ), weight loss (Fig. 2B) , diarrhea, ruffled fur, and skin lesions (data not shown). In contrast, histological analysis on day ϩ43 post-BMT. T CM caused statistically significant pathologic GVHD in the skin, liver, and small intestine ( Fig. 2C ; representative histology in Supplemental Fig.  1 ), whereas T N induced significant GVHD in these tissues and in the colon (Fig. 2C) . Although T CM did not induce GVHD in the colon (relative to BM alone controls), scores in comparison to T N recipients did not reach significance ( p ϭ 0.159). In the liver, aside from three mice with high scores, the majority of mice had relatively mild liver GVHD. Nonetheless, even if the scores from these mice are excluded or assigned a value of 5, the p value comparing liver GVHD in BM alone controls and T CM recipients is still significant ( p Յ 0.021), although this would render disease in T N recipients more severe than in T CM recipients ( p Յ 0.043). Thus, CD8
ϩ T CM induce GVHD in the C3H.SW3 B6 strain pairing. However, GVHD was clinically less severe than that induced by T N , and this difference may at least in part be explained by less colon and liver GVHD in T CM recipients.
To further investigate the nature of GVHD in B6 recipients of C3H.SW T CM , we performed immunofluorescence staining on small bowel specimens to identify infiltrating CD8 ϩ T cells. CD8 ϩ T cells invaded the mucosa with penetration into villi in both T CM and T N recipients, whereas such cells were rare in recipients of only TCD C3H.SW BM (Fig. 3A, representative images; Fig. 3B , number of CD8 cells/ϫ40 field). CD8 cells were more frequent in T CM and T N recipients than in recipients of only BM ( p ϭ 0.003), whereas counts in T CM and T N recipients were similar ( p ϭ 0.8).
Thus, T N -and T CM -derived effectors shared the ability to cause infiltrative GVHD of the small intestine.
CD8 ϩ T CM mediate GVL
To study the efficacy of CD8 ϩ T CM in mediating GVL, we used a mCP-CML created via retroviral transduction of BM cells with the human bcr-abl fusion cDNA (p210) (28, 29) . The construct also expresses a nonsignaling form of NGFR, which allows detection of mCP-CML cells by flow cytometry. mCP-CML is characterized by a high white blood cell count and splenomegaly, with hematopoiesis dominated by maturing myeloid cells (32, 33) . In the C3H.SW3 B6 strain pairing, GVL is directed toward miHA and not against p210 and NGFR (29, 34). B6 recipients were lethally irradiated and reconstituted with TCD C3H.SW BM, p210-infected B6 BM, and no C3H.SW T cells or 3 ϫ 10 5 CD8 ϩ T N or T CM . We chose a low dose of donor T cells that mostly prolong survival rather than curing 100% of mice, thereby allowing the detection of minor differences in the abilities of T N and T CM to induce GVL that could be masked by higher T cell doses. All mice that did not receive donor CD8 ϩ T cells died from mCP-CML by day 22. In contrast, recipients of either CD8 ϩ T N or T CM had prolonged survival with 1 of 10 in each group surviving to the end of the experiment at day 75 ( Fig. 4A ; all deaths were from mCP-CML). T CM -mediated GVL was not due to contaminating T N as recipients of 7.5 ϫ 10 3 CD8 ϩ T N (T N control ), the number of T N in the sorted CD8
ϩ T CM cells, died from mCP-CML with similar kinetics as did mice that received no donor T cells (Fig. 4A) . We serially analyzed PB using NGFR expression to identify mCP-CML cells (Fig. 4B, representative flow cytometry) . Overall, T N and T CM recipients had comparable numbers of NGFR ϩ cells (Fig.  4C) with T CM recipients having fewer NGFR ϩ cells on day ϩ11 ( p ϭ 0.0039), more on day ϩ18 ( p ϭ 0.0185), without statistically significant differences at the remaining time points. Similar results were observed when 1 ϫ 10 5 T N and T CM were used to induce GVL (data not shown). Thus, CD8
ϩ T N and T CM have comparable capacities to induce GVL. 
T CM and T N expansion, cytokine production and cytolytic activity post-alloBMT
To better understand how donor T CM and T N expand and mature into effectors after transfer, we analyzed progeny of T CM and T N 7 days after BMT in the B63 BALB/c model wherein GVHD was induced by 10 6 CD8 ϩ T N or T CM . We used CD45.1 ϩ and CD45.2 ϩ B6 mice as T cell and BM donors, respectively, so as to be able to clearly identify infused T N and T CM (BALB/c mice are CD45.2). As controls, we performed syngeneic B63 B6 transplants. Both BALB/c T CM and T N recipients had ϳ4 ϫ 10 6 and 4 ϫ 10 5 CD45.1 ϩ CD8 ϩ cells in spleen and LN, respectively ( To analyze differentiation into effectors, spleen and LN cells from transplant recipients (isolated on day ϩ7) were stimulated with PMA and ionomycin and analyzed by intracellular cytokine staining for the presence of IFN-␥ and TNF-␣. We observed little, if any, TNF-␣ production (Fig. 5A, representative staining) . However, ϳ40 -50% of CD8 ϩ CD45. ϩ CD45.1 ϩ IFN-␥ ϩ cells than did T N recipients, which paralleled the difference in overall numbers of donor-derived CD8 cells ( p ϭ 0.028). We were also interested in how well freshly isolated B6 CD8
ϩ T CM and T N produced IFN-␥ after PMA/ionomycin stimulation (Fig. 5E ). Only 9% of T N produced IFN-␥, and only weakly. In contrast, 70% of T CM produced IFN-␥, with a geometric mean expression ϳ6-fold higher than in T N . Nearly 25% of T CM brightly expressed IFN-␥ as compared with no IFN-␥-bright T N . In sum, after transfer to BALB/c recipients, T CM and T N similarly differentiated into IFN-␥-producing cells, although T CM may have already been polarized to do so.
We also analyzed serum samples taken on day ϩ7 from these transplant recipients for cytokines using the Bio-Plex system. We analyzed levels of IFN-␥, IL-2, TNF-␣ (Fig. 6) , IL-12, and GM-CSF (data not shown). Of these, only IFN-␥ was elevated in allogeneic recipients relative to syngeneic recipients ( p Ͻ 0.02 comparing T N or T CM in B63 BALB/c vs B63 B6 recipients). There was no difference in IFN-␥ levels in allogeneic T CM vs T N recipients ( p ϭ 0.41).
To compare cytolytic function of transferred T N and T CM , we injected 5 ϫ 10 6 CFSE-labeled B6 and 5 ϫ 10 6 CFSE-labeled BALB/c B cells into BALB/c mice that had been transplanted 7 days prior with TCD B6 BM, with no T cells or with 10 6 CD8 ϩ T N or T CM . Twenty hours later, mice were sacrificed, and the survival of CFSE ϩ B220 ϩ B6 and BALB/c cells in spleen and LN was assessed by flow cytometry. In recipients of only TCD BM, the ratio of infused B6 and BALB/c B cells was ϳ1:1 (Fig. 7) . In contrast, in both T N and T CM recipients, Ͼ94% of CFSE ϩ B220 ϩ cells were H-2K bϩ and therefore B6 in origin. Thus, both T N and T CM mediated potent killing of allogeneic BALB/c B cells, consistent with their GVL activities.
Discussion
Prior studies have shown that T EM not specifically primed to alloantigens are greatly impaired in their ability to induce GVHD (22-27, 35, 36 ). The capacity of T CM to do so has been less well studied, and one group recently reported in a single MHC-mismatched model that T CM do not cause GVHD (27) . In contrast to that study, in the present work, we clearly show in MHC-matched and MHC-mismatched strain pairs that CD8 ϩ T CM not specifically primed to alloantigens do cause clinical and pathologic GVHD. However, T CM were less potent as measured by weight loss and death and by less pathologic colonic GVHD in the C3H.SW3 B6 strain pairing. There was also a suggestion that overall, T CM -induced less severe liver GVHD in both models. Thus, our in-depth studies show that T CM are capable of inducing GVHD and that they differ substantially from T EM , but more subtly from T N .
In contrast to their abilities to induce GVHD, CD8 ϩ T CM and T N were comparable mediators of GVL as measured both by survival and by the numbers of NGFR ϩ mCP-CML cells in PB at several time points. For GVL experiments, we used a T cell dose well below that which cures 100% of mice so as to be able to detect small differences in T cell potency, making it unlikely that we missed a major difference. These data are consistent with prior work with TCR-transgenic T CM in an antitumor model (17, 19) . Thus, the selective infusion of T CM may be able to mediate GVL with less GVHD, although the reduction in GVHD may only be modest.
In our studies, T CM were not generated specifically against alloantigens. Rather, they likely differentiated into T CM after reacting against allergens or commensual and pathogenic organisms that can infect laboratory mice (37) (38) (39) (40) (41) (42) . Alternatively, these T CM phenotype cells could be the product of lymphopenia-induced proliferation, which occurs early in the development of the immune system (43) (44) (45) (46) . Consistent with having been previously activated, 70% of freshly isolated CD8
ϩ T CM produced IFN-␥ after PMA/ ionomycin stimulation. Regardless of their precise activation history, the T CM used in our studies clearly responded against both allogeneic MHC-peptide and syngeneic-MHC-miHA peptide complexes. Such cross-reactivity, or heterologous immunity, has been well demonstrated in T cells reactive against both allogeneic MHC (47-62) and against viral peptides on a shared MHC (61, (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) (73) , analogous to our results in the B63 BALB/c and C3H.SW3 B6 models, respectively. Alloreactive memory cells are thought to be barriers to successful solid organ transplantation (48, 51-53, 55, 74) , and the present data that T CM mediate both GVHD and GVL are consistent with these studies.
B6 CD8 ϩ T CM and T N similarly expanded by day ϩ7 in allogeneic recipients, and expansion of both was 20-to 30-fold greater than in syngeneic recipients. This difference highlights the alloreactivity in both populations. It is surprising that even though T CM and T N differ in TCR repertoire and in their prior activation history, that similar numbers accumulated in spleen and LN. In contrast, in syngeneic transplants, T CM expanded to larger numbers. These data suggest that there may be T cell intrinsic and/or extrinsic factors that restrict T cell expansion in allogeneic recipients, such as limitation on the amount of Ag (in this case in the form of recipient APC) or cytokines. This picture parallels observations in other models wherein the peak of Ag-driven T cell expansion is not directly proportional to the number of precursor cells that initially are activated (75, 76) .
Both T CM and T N progeny expressed effector functions in vitro and in vivo. Similar fractions of T N -or T CM -derived cells produced IFN-␥ in both syngeneic and allogeneic recipients, although a greater percentage of both T N and T CM were IFN-␥-bright in allogeneic recipients. Although we cannot determine whether IFN-␥-producing progeny of T CM were derived from cells that had previously been polarized to produce IFN-␥, given that 70% of freshly isolated T CM produce IFN-␥, it is reasonable to suggest that the precursors of many of the T CM progeny were already polarized. In contrast, most T N were likely polarized after transfer in both syngeneic and allogeneic recipients. Allogeneic T N or T CM recipients also had elevated serum IFN-␥ levels, which roughly paralleled the numbers of IFN-␥-producing cells.
We also compared CTL activity of T N and T CM progeny against allogeneic targets in vivo, and both specifically killed BALB/c B cells relative to syngeneic B6 B cells. These data do not address the frequency of T N -or T CM -derived CTL that recognize allogeneic targets or their specific potencies on a per cell basis; however, they clearly demonstrate that both T CM and T N differentiate into CTL as indicated in the GVL experiments.
Our results differ from those of Chen et al. (27) who reported that a mix of CD4 ϩ and CD8 ϩ T CM induced neither clinical nor histological GVHD in the B63 BALB/c strain pairing, which we also used. In that study, T CM were identified as being CD62L ϩ
CD44
ϩ CD45RB ϩ , whereas we did not stain for CD45RB. In our hands and in their published data, CD8 ϩ CD62L ϩ CD44 ϩ cells are all CD45RB
ϩ , and therefore, the inclusion of CD45RB should not have resulted in their sorting a population distinct from that in our work. In their experiments, 10 6 total T CM were transferred, of which approximately half were CD8
ϩ . Thus, it is possible that GVHD was not induced because fewer CD8
ϩ T CM were transferred. If so, then 5 ϫ 10 5 CD4 ϩ T CM must neither induce GVHD nor promote the activation of alloreactive CD8 ϩ T CM . The failure of a mix of CD4 ϩ and CD8 ϩ T CM to induce GVHD was not due to CD62L ϩ CD44 ϩ CD4 ϩ CD25 ϩ regulatory T cells as in their studies, when these cells were depleted, T CM still did not induce GVHD. CD4
ϩ T CM may in some other way reduce the capacity of CD8 ϩ T CM to cause GVHD, although this is not generally the case with unfractionated CD4 and CD8 cells in GVHD models (77) .
We point out that Chen et al. (27) reported a negative result, whereas we report a positive one-that is, T CM induced both GVHD and GVL. Therefore, one must consider other possible reasons that Chen et al. (27) failed to make this observation. It is conceivable that the cell-sorting procedure these investigators used sufficiently reduced the viability, survival after transfer, or functionality of T CM so as to result in an underestimation of their GVHD-inducing potential. In their experiments, sorted T CM contained 3% and therefore 30,000 T N , whereas 10,000 unfractionated T cells (of which only ϳ50% were naive) that did not undergo cell sorting, induced death and weight loss in BALB/c recipients. Therefore, if the majority of sorted cells were viable, one would have anticipated that some GVHD would have been seen in recipients of 30,000 contaminating T N , unless this was suppressed by the majority T CM . It is also possible that Ab bound to CD45RB altered the survival or function of the sorted T CM (78) . Regardless of why our results differ, our data are a critical contribution in showing with multiple models, that CD8 ϩ T CM indeed do cause GVHD.
As to why CD8 ϩ T CM have a greater capacity to induce GVHD than do CD8 ϩ T EM , we see several hypotheses. One possibility is that T CM may have a broader TCR repertoire that includes more receptors that recognize alloantigens. In humans, T EM and T CM have distinct but similarly complex repertoires (79) . However, it is difficult to extrapolate these data to laboratory mice in which the repertoire of these subsets is less likely to have been shaped by constant exposure to pathogens. T CM may be more efficiently activated after transfer due to better access to LN and Peyer's patches (PP), because of their expression of CD62L and CCR7. Such a mechanism has been postulated to at least in-part explain why in vitro generated CD8
ϩ TCR-transgenic T CM were more potent in an antitumor model than were T EM (17) . However, it was recently shown that T N induce robust GVHD in mice that nearly completely lack LNs and PP (80, 81) . Nonetheless it remains to be tested whether T CM are more reliant on priming in those sites than are T N . Another possibility is that T CM are more capable than T EM of undergoing clonal expansion. T CM have a greater in vitro proliferative capacity (reviewed in Ref. 10 ). In vivo, adoptively transferred TCR-transgenic T CM provide greater protection from LCMV infection than do adoptively transferred T EM , and this was shown to be due to a greater proliferative capacity of T CM (11) . The relative abilities of CD8 ϩ T EM and T CM to protect from pathogens is model-dependent and features other than proliferative capacity play a role; nonetheless, overall T CM seem to have a greater ability to undergo clonal expansion (reviewed in Ref. 20) . These types of quantititative analyses are not possible in our studies, which used naturally occurring polyclonal T CM , due to the inability to identify miHA-stimulated T cells and distinguish them from those that underwent lymphopenia-induced proliferation. In alloBMT models, CD4 ϩ T EM do not accumulate as well as T N (23, 26) , but again T cells activated by alloantigen could not be distinguished from those that underwent lymphopenia-induced proliferation.
A related question is why T CM induced milder clinical and subtly less pathologic GVHD than did T N . Both T N and T CM have ready access to LN and PP due to their expression of CD62L and CCR7. Also, our data demonstrated that both T N -and T CM -derived effectors were able to infiltrate target tissues (Fig. 3) . However, T CM may more readily migrate directly into tissues after infusion, thereby effectively reducing the number of cells available for activation in secondary lymphoid tissues. For example, T CM more efficiently enter BM spaces (82) . Nonetheless, by day 7 there were comparable numbers of T CM -and T N -derived cells in both spleen and LN. T CM may have a less alloreactive TCR repertoire than do T N , and again this could be more applicable in humans wherein the TCR repertoire of memory phenotype cells is more likely to have been shaped and narrowed by pathogens (83) (84) (85) (86) . In MHCmatched, multiple miHA-disparate transplants, not only could the frequency of alloreactive T cells be reduced overall in T CM , but the specific miHA targeted could be different as the TCR repertoire can impact on the choice of immunodominant Ags (87) (88) (89) (90) (91) . Thus, T CM could have chosen a different set or hierarchy of immunodominant Ags, which is known to be a property of T cell responses to miHAs (92) (93) (94) .
There could also be differences in other intrinsic properties of the progeny of activated T N and T CM , such as the types of cytokines elaborated, expression of cytotoxic granules, TNF family ligands and resistance to activation-induced cell death. At a minimum we know that in the B63 BALB/c model, T N -and T CMderived cells both produced IFN-␥ and had cytolytic function in vivo. However, given that such a high frequency of freshly isolated T CM produced IFN-␥, it is likely that a substantial fraction of alloreactive T CM were already programmed. It is possible that they differentiated into effectors less capable of causing disease than did T N only activated in BMT recipients. Investigating potential differences between T CM and T N will require comparing in GVHD models T N genetically deficient in candidate molecules by which they may differ from T CM (reviewed in Refs. [95] [96] [97] to intact T CM ; given the likelihood that multiple factors contribute and the relatively mild quantitative differences in GVHD induction, such studies are not likely to be informative.
A complete understanding of the relative potencies and mechanisms of action of T CM , T EM , and T N in GVHD and GVL models will require experimental systems wherein donor T N , T CM , and T EM have equivalent and defined TCR repertoires, which would help to control at least some of these variables. Nonetheless, with available systems, it is important conceptually, mechanistically and clinically to know that CD8 ϩ T CM can cause both GVHD and GVL, in contrast to what was previously thought (27) .
